Bloomberg examines America’s CBD Boom

Bloomberg sheds light on the fast-growing CBD industry in “America’s CBD Boom: Brazen Claims, Fake Products, Regulatory Scrutiny” by Craig Giammona and Kristine Owram (Feb. 19, 2019) and uncovers a few of the many questions that exist around the much-hyped component of hemp. Showing up in a multitude of drinks, treats, tinctures, lotions and even bath salts, CBD is generally safe but has not been put up to the essential scrutiny at the federal level.

CCD Helmsman’s Kara Nielsen points out, “America has always had a population looking for the silver bullet. The hype follows a similar pattern: It has a lot going for it, but it’s unclear exactly what it does so it allows people to imagine it’s their solution.”

With the December passage of the U.S. Farm Bill, certain chemical compounds in hemp, including CBD, are legal under certain circumstances, but now under FDA authority. Consequently, CBD products with therapeutic claims must be approved for intended use before being introduced into interstate commerce. Regulators are starting to pay closer attention to the myriad beverages and foods with CDB.  

It’s a complex affair related to the source of CBD, the fact that a drug maker is testing CBD in a pharmaceutical, future FDA hearings and many more factors. Read more here: “FDA commissioner is ‘deeply focused’ on CBD issues” by Josh Long, Natural Products Insider, March 1, 2019.

#CBD #CannibisCannabis #CBDFood #Bloomberg

Image credit: CBD Oil is Here | Photographer: Jennifer Lett | South Florida Sun-Sentinel via AP Photo

Kara Nielsen